199 related articles for article (PubMed ID: 15205684)
1. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.
Kaimaktchiev V; Terracciano L; Tornillo L; Spichtin H; Stoios D; Bundi M; Korcheva V; Mirlacher M; Loda M; Sauter G; Corless CL
Mod Pathol; 2004 Nov; 17(11):1392-9. PubMed ID: 15205684
[TBL] [Abstract][Full Text] [Related]
2. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
3. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
Werling RW; Yaziji H; Bacchi CE; Gown AM
Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
[TBL] [Abstract][Full Text] [Related]
4. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
5. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
Sullivan LM; Smolkin ME; Frierson HF; Galgano MT
Am J Surg Pathol; 2008 Nov; 32(11):1608-12. PubMed ID: 18753946
[TBL] [Abstract][Full Text] [Related]
9. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
11. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
12. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
Leite KRM; Mitteldorf CATS; Srougi M; Dall'Oglio MF; Antunes AA; Pontes J; Camara-Lopes LH
Ann Diagn Pathol; 2008 Aug; 12(4):260-266. PubMed ID: 18620992
[TBL] [Abstract][Full Text] [Related]
13. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
14. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
15. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas.
Dursun N; Escalona OT; Roa JC; Basturk O; Bagci P; Cakir A; Cheng J; Sarmiento J; Losada H; Kong SY; Ducato L; Goodman M; Adsay NV
Arch Pathol Lab Med; 2012 Nov; 136(11):1347-58. PubMed ID: 23106580
[TBL] [Abstract][Full Text] [Related]
16. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas.
Sen A; Mitra S; Das RN; Dasgupta S; Saha K; Chatterjee U; Mukherjee K; Datta C; Chattopadhyay BK
Indian J Pathol Microbiol; 2015; 58(2):158-62. PubMed ID: 25885126
[TBL] [Abstract][Full Text] [Related]
17. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
Bakaris S; Cetinkaya A; Ezberci F; Ekerbicer H
Histol Histopathol; 2008 Sep; 23(9):1043-7. PubMed ID: 18581275
[TBL] [Abstract][Full Text] [Related]
18. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays.
Moskaluk CA; Zhang H; Powell SM; Cerilli LA; Hampton GM; Frierson HF
Mod Pathol; 2003 Sep; 16(9):913-9. PubMed ID: 13679455
[TBL] [Abstract][Full Text] [Related]
19. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
20. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
Park KJ; Bramlage MP; Ellenson LH; Pirog EC
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):8-11. PubMed ID: 18776815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
